PROGEN’s p53 antibodies – trusted antibodies for cell cycle research
p53 mouse monoclonal antibodies
- Excellent marker for wild-type and mutant human p53
- Different antigens & application formats
- Antibodies stain approx. 60% of investigated carcinoma
- Positive targets: tumors of lung, breast, colon, stomach, esophagus, pancreas, urinary bladder and testis, head and neck; T-cell Leukemia, non-Hodgkin-Lymphoma, melanoma, sarcoma
Publications
- Ohtaké, S. et al. Precancerous foci in pleomorphic adenoma of the salivary gland: recognition of focal carcinoma and atypical tumor cells by P53 immunohistochemistry. J. Oral Pathol. Med. 31, 590–7 (2002).
- Homann, N. et al. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma. Clin. Cancer Res. 7, 290–296 (2001).
- Vispo, N. S., Araña, M. J., Chinea, G., Ojalvo, a G. & Cesareni, G. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. Hybridoma 18, 251–255 (1995).
- Petersen, G., Song, D., Hugle-Dorr, B., Oldenburg, I. & Bautz, E. K. Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Mol Gen Genet 249, 425–431 (1995).
- Bártek, J. et al. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol. 169, 27–34 (1993).